Archive | Redefining Every Stage Investments (RESI) RSS feed for this section

New Aging & Longevity Track Launches at RESI Boston via Partnership Between Longevity Global and Life Science Nation 

1 Jul

By Matt Stanton, VP Sales US West, Central and South America, LSN

Longevity Global (LG) and Life Science Nation (LSN) are proud to announce a new partnership to launch a dedicated Aging & Longevity Track at the upcoming RESI (Redefining Every Stage of Investments) Boston Conference this September. This collaboration brings together two leading organizations committed to advancing innovation in healthcare and biotech, positioning longevity-focused startups at the center of global investor and partner engagement.

The Aging & Longevity Track will serve as a curated platform for Longevity Global’s community of founders, researchers, and entrepreneurs to connect with LSN’s expansive partnering ecosystem, including global capital investors and licensing partners. Participating companies will gain access to panels, workshops, educational sessions, and networking opportunities tailored to early-stage ventures across the healthcare spectrum. Longevity Global attendees will also have the option to upgrade to RESI’s renowned one-on-one partnering platform, which allows them to connect directly with strategic partners and capital sources.

“This collaboration gives our longevity ecosystem direct access to global capital and strategic relationships that can accelerate the path from research to real-world impact,” said Christin Glorioso, Founder and CEO at Longevity Global. “The opportunity to plug into RESI’s cross-sector audience while bringing aging science to the forefront is a huge step forward for our mission.”

LSN also views this partnership as a powerful gateway to expand its reach within the rapidly growing longevity sector. “Longevity is one of the most promising frontiers in healthcare, and we’re excited to help emerging companies in this space connect with the capital and partners they need to scale,” said Dennis Ford, CEO of Life Science Nation. “Partnering with Longevity Global allows us to provide a highly curated experience that meets the needs of this evolving vertical.”

About Longevity Global
Longevity Global is a mission-driven community and event platform that connects scientists, startups, and investors working to solve aging. As a branch of Academics for the Future of Science, a 501(c)(3) nonprofit, LG curates events and programs across San Francisco, New York, Boston, the UAE, and beyond.

About Life Science Nation & RESI
Life Science Nation (LSN) is a global partnering platform for every stage of life science companies, offering a suite of tools that includes a database of over 6,000 investors, RESI partnering conferences, and commercialization support. RESI events connect startups with investors and strategic partners across drugs, devices, diagnostics, and digital health.

For more information about RESI Boston September 2025 conferences, contact us at resi@lifesciencenation.com.

Tags: , , , , , , , ,

Why Startups Struggle to Get Investor Meetings – And How to Fix It 

1 Jul

By Karen Deyo, VP of Product, Israel BD, LSN

karen-wpOne of the biggest challenges startups face when raising capital is simply getting in front of investors. Securing that first meeting often requires significant effort, and when outreach goes unanswered, founders are left wondering: Are they not interested? Are they just too busy? More often than not, the issue isn’t the technology – it’s the messaging. Without clear, concise, and compelling messaging, startups struggle to cut through the noise and grab investor attention.

Over the years, Life Science Nation (LSN) has developed a comprehensive library of educational content to guide first-time CEOs through the complexities of launching a successful partnering campaign. One of the most critical – and overlooked – components is messaging. Investors are inundated with inbound requests, and your company should make it as easy as possible for them to say “yes” to a meeting – ideally just from reading your tagline and elevator pitch. When working with scientist-entrepreneurs, we often go through 20–30 iterations of a company’s core messaging before it clicks. It’s hard work, but it pays off.

Another common pitfall: focusing too heavily on the science. Investors aren’t just investing in technology – they’re investing in companies. A strong scientific story is important, but it must be framed within a broader business narrative. Founders often get valuable feedback during their campaign, but the most successful teams anticipate objections and refine their story before they launch.

That’s why LSN created a structured messaging assessment tool to help companies get a head start. We’ve developed a proprietary questionnaire that, combined with your current marketing collateral, allows our AI agent to evaluate your messaging readiness and identify areas for improvement.

The assessment includes a first-pass tagline and elevator pitch based on our proven messaging criteria, along with an analysis across eight key areas – from management team to competitive landscape – to highlight potential weaknesses in your strategy.

We’re offering this service free of charge as part of our mission to help startups overcome the hidden obstacles that make fundraising so difficult. Click the link below to fill out the questionnaire – and we’ll be in touch with your personalized assessment soon.

RESI Boston IPC Winners Announced – Now Accepting Applications for September 

24 Jun

By Max Braht, Director of Business Development, LSN

Max-Braht-HeadshotAt RESI Boston June 2025, 53 companies participated in the Innovator’s Pitch Challenge (IPC), presenting their technologies to panels of active investors and showcasing their work in the Exhibition Hall. RESI attendees — including early-stage investors, startup executives, and industry leaders — voted for the most impressive companies based on pitch presentations, Q&A performance, and networking in the exhibit hall.

Congratulations to the Top-Ranked IPC Companies from RESI Boston June

First Place: MindLab

Our lead product, MLB-001, is a first-in-class, combination drug designed to deliver powerful, life-changing pain relief using significantly lower morphine doses. MLB-001 achieves equal or superior analgesic effects compared to conventional morphine, while minimizing common side effects and reducing the development of drug tolerance. Importantly, MLB-001 is specifically engineered to lower the risk of addiction, a critical advancement given the ongoing opioid crisis. MindLab is committed to redefining pain care by introducing safer, more effective treatments that address unmet medical needs and promote better quality of life for patients worldwide.

Sougato Das, President and COO, Life Science Nation | Larry Raoul James JD, MBA, Founder, President, and CEO of MindLab | Dennis Ford, Founder & CEO, Life Science Nation

Second Place: Inomagen Therapeutics

Inomagen Therapeutics, Inc. is a private, preclinical stage biotechnology company pioneering a gene therapy to improve the treatment of atrial fibrillation. Inomagen has intellectual property and proof of concept data for both the gene and the gene delivery system. Inomagen has a strong and experienced team of industry veterans and key opinion leading cardiovascular physicians to engage in management and advisory roles, including those with extensive domain experience in gene therapy, cardiology, AF therapeutics, medical device, clinical studies, and venture capital. The market size for Inomagen’s gene therapy products is $10.2B.

Sougato Das, President and COO, Life Science Nation | Eric Sandberg, CBO, Inomagen Therapeutics | Robin Drassler, VP of Business Development, Inomagen Therapeutics | Dennis Ford, Founder & CEO, Life Science Nation

Third Place: MantaBio

MantaBio is a life sciences tools company building automated microbial detection systems specifically designed for biopharma manufacturing environments. Our platform offers rapid, high-sensitivity detection across all microbe categories: bacteria, fungi, viruses, and mycoplasma — delivering results in just 2 hours compared to the industry standard of 5 to 28 days. Built with the needs of biologics producers in mind, MantaBio’s technology is optimized for speed, accuracy, and ease of use. It requires less than one minute of hands-on time, no specialized training, and integrates seamlessly into GMP workflows. By enabling at-line or near-line testing with gold-standard sensitivity, MantaBio helps manufacturers reduce contamination risk, minimize batch loss, and accelerate product release timelines. Our system is the next generation in microbial quality control — replacing outdated manual culture methods and reliance on off-site reference labs with a modern, automated approach built to match the pace and complexity of today’s biopharma processes.
Sougato Das, President and COO, Life Science Nation | Max Braht, Director of Business Development, Life Science Nation | Carter Boisfontaine, Co-Founder and President, MantaBio | Dr. Jack Regan, Co-Founder, CEO, and CTO, MantaBio | Claire Jeong, CCO, Vice President of Investor Research, Asia BD, Life Science Nation | Dennis Ford, Founder & CEO, Life Science Nation

We applaud all IPC participants for sharing their innovative work and contributing to a dynamic, high-impact event.

Applications Now Open for the September IPC at RESI Boston

The Innovator’s Pitch Challenge at RESI Boston September offers life science startups the opportunity to present directly to a curated panel of active investors and receive real-time, constructive feedback. Each pitch includes a live Q&A with investor judges and extended exposure through participation in the IPC exhibition hall.

New for September, the IPC package now includes the option to add a second three-day standard ticket at no additional cost. This provides a teammate with full access to partnering and conference sessions.

Benefits include:

  • Investor feedback during live pitch sessions
  • Full access to one-on-one partnering
  • Exhibit table in the IPC Hall
  • Optional additional RESI pass included

Apply now to secure your spot and connect with global early-stage investors this September.

Apply to Pitch at RESI Boston Sept. 2025

Tags: , , , ,

Investor Panels at RESI Boston September

24 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston returns on September 17, 2025 at the Westin Copley Place, once again serving as a core event during Biotech Week Boston. Organized by Life Science Nation, RESI (Redefining Every Stage of Investment) brings together life science and healthcare companies with hundreds of investors and strategic partners for a day of partnering, networking, educational content, and exhibits.

A highlight of every RESI conference is the investor panel programming, where active investors and strategics speak directly to entrepreneurs about what they’re looking for, how they invest, and how startups can position themselves for success. The upcoming September event will feature deep dives into some of the most dynamic areas of healthcare innovation, featuring speakers from impact investors, corporate venture arms, Big Pharma, family offices, and more.

Impact Investors & Venture Philanthropy Panel

The Role of Impact Investing in the Healthcare Ecosystem

Impact investors and venture philanthropists are playing a growing role in backing early-stage healthcare ventures, especially those addressing health equity and underserved areas. In this panel, leaders in the field will discuss how they define and measure impact, what they look for in mission-driven ventures, and how they work with founders to align values with milestone-based progress. Attendees will gain insight into how this capital is deployed to catalyze innovations that go beyond traditional ROI.

Mental & Behavioral Health Panel

Investing in Solutions for Higher Quality of Life and Wellbeing

With 1 in 8 people globally affected by mental disorders, demand for novel solutions in behavioral health continues to grow. This panel features investors who are actively backing companies developing digital tools, neurotechnologies, care delivery innovations, and novel therapeutics. Panelists will explore challenges such as stigma, reimbursement, and regulation—along with what it takes for startups to stand out in this vital and rapidly evolving market.

Oncology Innovation Panel

Latest Scientific Breakthroughs and Future Outlook

Oncology continues to attract robust investor interest, yet the bar for scientific rigor and differentiation is high. This session gathers investors focused on oncology diagnostics, therapeutics, and platforms to discuss what excites them in the current landscape and what it takes to succeed. Topics include scientific novelty, clinical de-risking, commercial potential, and where the next wave of oncology innovation may arise.

Corporate VC Panel

Venture and Innovation Arms Making Strategic Investments

Corporate VCs offer much more than capital, they bring strategic alignment, deep expertise, and long-term partnership opportunities. In this session, leaders from CVC arms of major pharma, biotech, and medtech companies will discuss how they source and evaluate early-stage deals, what startups should expect post-investment, and how founders can navigate alignment with a corporate parent. This panel is essential for startups seeking strategic investors.

Diagnostics Panel

Investing in Innovations for Preventative and Personalized Care

As diagnostics become increasingly central to precision medicine and population health, investors are paying close attention. Panelists in this session will discuss how they evaluate new diagnostic technologies, from regulatory and reimbursement outlooks to commercial differentiation and unmet need. For entrepreneurs developing platforms in oncology, infectious disease, or chronic conditions, this discussion will provide actionable guidance on positioning and funding strategies.

Partnering with Big Pharma Panel

What Startups Need to Know to Get on Big Pharma’s Radar

Securing a partnership with Big Pharma can be a transformative milestone. This panel features business development and venture leaders from leading pharmaceutical companies who will share what they look for in early-stage collaborations. Learn how they assess risk, stage readiness, and strategic fit—plus how startups can build compelling cases for co-development, licensing, or investment.

Family Offices Panel

Perspectives on Early-Stage Investments

Family offices have become increasingly visible in early-stage healthcare deals, often offering patient capital and values-driven investment strategies. This panel will unpack how these investors approach opportunity evaluation, what sets them apart from traditional VCs, and how they support portfolio companies beyond capital. Attendees will also hear practical advice for engaging family offices and building meaningful relationships.

Whether you’re developing breakthrough diagnostics, therapeutics, platforms, or care delivery solutions, the RESI Boston investor panels offer a unique opportunity to hear directly from the funders shaping the future of healthcare.

Interested in sharing your insights at RESI? Reach out to join our speaker lineup!

Register by July 11 to lock in Super Early Bird Rates and save $300. Secure your spot today and join 400+ investors and strategic partners this September in Boston.

Tags: , , , , ,

Introducing BD Assist: LSN Sets Up the Meetings For Your Global Investor Roadshow

24 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022Life Science Nation (LSN) pioneered investor engagement through its RESI Conferences, global investor database, and entrepreneurial education programs. LSN is taking a significant leap forward with the launch of BD Assist, a full-service investor outreach and meeting management product designed to augment and complement your in-house BD efforts.

With BD Assist, LSN aids in the tedious task of booking meetings with your partner targets:

  • LSN Labs AI Agent will optimize your messaging for outreach.
  • Identify and prioritize well-matched capital and licensing partners
  • Conduct coordinated outreach
  • Schedule and confirm investor meetings on your behalf

The product development, regulatory, and operational complexities of running a life science company are already challenging enough. BD Assist removes one of the most tedious but significant burdens: finding, securing, and managing investor meetings.

Why LSN Is Uniquely Positioned to Do This
LSN combines getting the right target list, a proven canvassing and follow-up methodology, and a dedicated outreach team to deliver results. LSN is a well-known, trusted, and credible entity in the partnering space. We know what life science investors are looking for and which meetings they’ll take. Over the past decade, we’ve taught hundreds of startups how to craft their story, manage outreach, and execute CRM-powered campaigns. The results are real; see our Australian accelerator cohort, where 90% of companies secured funding or strategic partnerships.

BD Assist takes on the daily work of driving your campaign forward. We handle the outreach, schedule your meetings, manage follow-up, and sync it all to your CRM in real time. You stay focused on the science, and we set up the business development meetings. If you’re raising capital or licensing in the next 12 months, BD Assist is your opportunity to launch a turnkey global campaign without hiring a whole BD team.

Ready to activate your global roadshow?
Contact us at salescore@lifesciencenation.com to get started.

Tags: , , , , , , ,

The RESI Boston June 2025 Program Guide Release

10 Jun

By Dennis Ford, Founder & CEO, Life Science Nation (LSN)

DF-News-09142022The official program guide for RESI Boston, June 2025 is now available! Redefining Every Stage of Investment (RESI) is built to connect life science and healthcare innovators with a global network of investors representing a wide range of funding strategies, from Seed through Series B and beyond.

This guide provides an overview of what to expect throughout the conference, detailing all of the content and layout for our in-person event on June 16th. Inside, you’ll find the full agenda, speaker bios, panel descriptions, and key information to help you navigate your RESI experience. Whether you’re participating in investor meetings, pitch sessions, workshops, or ad hoc networking, this guide is your resource to stay informed and get the most out of RESI Boston.

Access the full guide here:

Tags: , , , , ,

Introducing the Investor Judges for the Innovator’s Pitch Challenge at RESI Boston 

10 Jun

By Claire Jeong, Chief Conference Officer, Vice President of Investor Research, Asia BD, LSN

RESI Boston takes place on June 16, and Life Science Nation is pleased to announce the investor judges participating in this event’s Innovator’s Pitch Challenge (IPC). With more than 50 companies presenting across 14 sessions, the IPC offers life science startups a high-impact opportunity to gain visibility, pitch directly to active investors, and receive valuable feedback in real time.

Each session will feature investor and strategic partner judges with expertise spanning therapeutics, medical devices, diagnostics, digital health, and life science tools. Following every pitch, judges will lead a live Q&A to assess the opportunity and share insights from the investor perspective.

Every IPC company will also have a dedicated table in the RESI Exhibition Hall, making it easy for attendees to connect with founders and learn more.

All registered attendees will be invited to vote online for their favorite companies, and the Top 3 companies will be announced at the end of the day’s cocktail reception. Winners will receive a prize and be featured in an upcoming issue of the LSN newsletter.

Scroll down to see which investors will serve as judges for this year’s IPC:

John Abeles
John Abeles
General Partner
Northlea Partners 		Chris Aleong
Chris Aleong
VP
BioIdeations 		Christina Ansted
Christina Ansted
Sr. Managing Partner
RCP Venture Capital
Jit Basak
Jit Basak
Investor
Launchit Ventures 		Jay Batchu
Jay Batchu
Entrepreneur in Residence
Xontogeny 		Randy Berholtz
Randy Berholtz
Sr. Advisor
Mesa Verde Venture Partners
Jeff Berman
Jeff Berman
Managing Partner & Co-Founder
Big Tree Innovation Fund 		Kalyan Chakravarthy
Kalyan Chakravarthy
Sr. Manager, External Innovation
Ipsen S.A. 		Jo Chaturvedi-Durant
Jo Chaturvedi-Durant
Sr. Investor & Venture Partner
VU Venture Partners
Shailesh Chavan
Shailesh Chavan
Managing Partner
Transatlantic Life Science Venture 		Nicolas Cindric
Nicolas Cindric
Partner
Yahara Ventures 		Javier Coindreau
Javier Coindreau
General Partner (Boston)
Sila B Health Ventures
Bettina Ernst
Bettina Ernst
Director
BERNINA BioInvest 		Alex Fair
Alex Fair
Managing Partner
Medstartr Capital 		Dimitra Georganopoulou
Dimitra Georganopoulou
Managing Director
Qral Ventures
Serban Georgescu
Serban Georgescu
Due Diligence Chair
Mass Medical Angels 		Ken Grise
Ken Grise
Principal
Sixty Degree Capital 		Marco Gulla
Marco Gulla
Investment Associate
Health Technology Holding (HTH)
George Hong
George Hong
Investor
H Advisor Group 		Guanghui Hu
Guanghui Hu
Venture Partner & CEO
Viva BioInnovator 		Kristin King-Jankiewicz
Kristin King-Jankiewicz
Member & Head of Group Management
Boston Harbor Angels
Claire Leurent
Claire Leurent
Managing Director
AbbVie 		Vivian Li
Vivian Li
SA
K2 Venture Partners 		Ali Malihi
Ali Malihi
President
Back Bay Group
Nune Martiros
Nune Martiros
Sr. Associate
Paladin Capital Group 		Jim McGough
Jim McGough
Managing Partner
Mid Atlantic Bio Angels 		Ralph Morales III
Ralph Morales III
Venture Partner / Executive-in-Residence
Aquillius Ventures
Jose Navarro
Jose Navarro
Scientific Director & Partner
quadraScope Venture Fund 		Lizzie Ngo
Lizzie Ngo
Principal
Longwood Fund 		Yoichi Omae
Yoichi Omae
BD Director
Asahi Intecc USA Inc
Soyoung Park
Soyoung Park
General Partner
1004 Venture Partners 		Chandra Ramanathan
Chandra Ramanathan
VP and Head of External Innovation, Life Sciences Innovation Group
Danaher Corporation 		Nans Rivat
Nans Rivat
VP
PACE Healthcare Capital
Shreya Sawant
Shreya Sawant
Venture Partner
Aquillius Ventures 		Pranav Seshadri
Pranav Seshadri
Investor
T.Rx Capital 		Jason Shieh
Jason Shieh
Partner/Co-Founder
HelixPoint Capital
Oliver Sims
Oliver Sims
Investment Manager
Octopus Ventures 		Alex Spicer
Alex Spicer
M&A Associate
SERB Pharmaceuticals 		Sri Sriadibhatla
Sri Sriadibhatla
Director, Healthcare Investment Group
Ben Franklin Technology Partners of Southern Pennsylvania
Isaac Stoner
Isaac Stoner
EIR
Slater Technology Fund 		Asad Taherbhoy
Asad Taherbhoy
Angel Investor
Angel Star Ventures 		Wei Tao
Wei Tao
Board Director & Chair, Bio/Genomics
Life Science Angels
Vince Wong
Vince Wong
CEO and President
BioCrossroads 		Chris Yoo
Chris Yoo
General Partner and Managing Director
Xcellerant Ventures 		Doug Zingale
Doug Zingale
Co-Founder & Managing Partner
Blue Goose Capital
Patrick-Cooke
Patrick Cooke, PhD
Associate
Merck Digital Sciences Studio 		SERB Pharmaceuticals
Samuel Freedman
M&A Analyst
SERB Pharmaceuticals

Tags: , , , , ,

← Older Entries
Newer Entries →